Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 1;4(4):e217746.
doi: 10.1001/jamanetworkopen.2021.7746.

Genomic Epidemiology of SARS-CoV-2 Infection During the Initial Pandemic Wave and Association With Disease Severity

Affiliations

Genomic Epidemiology of SARS-CoV-2 Infection During the Initial Pandemic Wave and Association With Disease Severity

Frank P Esper et al. JAMA Netw Open. .

Abstract

Importance: Understanding of SARS-CoV-2 variants that alter disease outcomes are important for clinical risk stratification and may provide important clues to the complex virus-host relationship.

Objective: To examine the association of identified SARS-CoV-2 variants, virus clades, and clade groups with disease severity and patient outcomes.

Design, setting, and participants: In this cross-sectional study, viral genome analysis of clinical specimens obtained from patients at the Cleveland Clinic infected with SARS-CoV-2 during the initial wave of infection (March 11 to April 22, 2020) was performed. Identified variants were matched with clinical outcomes. Data analysis was performed from April to July 2020.

Main outcomes and measures: Hospitalization, intensive care unit (ICU) admission, mortality, and laboratory outcomes were matched with SARS-CoV-2 variants.

Results: Specimens sent for viral genome sequencing originated from 302 patients with SARS-CoV-2 infection (median [interquartile range] age, 52.6 [22.8 to 82.5] years), of whom 126 (41.7%) were male, 195 (64.6%) were White, 91 (30.1%) required hospitalization, 35 (11.6%) needed ICU admission, and 17 (5.6%) died. From these specimens, 2531 variants (484 of which were unique) were identified. Six different SARS-CoV-2 clades initially circulated followed by a rapid reduction in clade diversity. Several variants were associated with lower hospitalization rate, and those containing 23403A>G (D614G Spike) were associated with increased survival when the patient was hospitalized (64 of 74 patients [86.5%] vs 10 of 17 patients [58.8%]; χ21 = 6.907; P = .009). Hospitalization and ICU admission were similar regardless of clade. Infection with Clade V variants demonstrated higher creatinine levels (median [interquartile range], 2.6 [-0.4 to 5.5] mg/dL vs 1.0 [0.2 to 2.2] mg/dL; mean creatinine difference, 2.9 mg/dL [95% CI, 0.8 to 5.0 mg/dL]; Kruskal-Wallis P = .005) and higher overall mortality rates (3 of 14 patients [21.4%] vs 17 of 302 patients [5.6%]; χ21 = 5.640; P = .02) compared with other variants. Infection by strains lacking the 23403A>G variant showed higher mortality in multivariable analysis (odds ratio [OR], 22.4; 95% CI, 0.6 to 5.6; P = .01). Increased variants of open reading frame (ORF) 3a were associated with decreased hospitalization frequency (OR, 0.4; 95% CI, 0.2 to 0.96; P = .04), whereas increased variants of Spike (OR, 0.01; 95% CI, <0.01 to 0.3; P = .01) and ORF8 (OR, 0.03; 95% CI, <0.01 to 0.6; P = .03) were associated with increased survival.

Conclusions and relevance: Within weeks of SARS-CoV-2 circulation, a profound shift toward 23403A>G (D614G) specific genotypes occurred. Replaced clades were associated with worse clinical outcomes, including mortality. These findings help explain persistent hospitalization yet decreasing mortality as the pandemic progresses. SARS-CoV-2 clade assignment is an important factor that may aid in estimating patient outcomes.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Esper reported receiving personal fees from MSL Group for serving as an advisory board member outside the submitted work. Dr Cheng reported receiving grants from the National Cancer Institute and personal fees from GLG Consulting, Putnam Associates, and Health Advances outside the submitted work. Dr Adhikari reported receiving grants from National Science Foundation outside the submitted work. Dr Chan reported receiving stock from Gritstone Oncology, personal fees from NysnoBio, and grants from Pfizer, Illumina, and AstraZeneca outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. SARS-CoV-2 Clade Prevalence Over the Initial Pandemic Wave
Genotypes of selected clinical samples were determined and categorized into Global Initiative on Sharing All Influenza Data (GISAID) clade. A, Weekly prevalence for each individual clade is displayed. GISAID clades were further clustered into 2 clade groups depending on the presence of the G614D spike glycoprotein variant (black dashed line). B, Phylogenetic tree constructed against the reference genome (NC_045512.2) using all samples. Timeline is displayed on the x-axis. The leaves are colored according to the GISAID clade, whereas the branches are labeled using NextStrain clade ID. The 2 systems are mostly consistent with each other. aComparison of clade group prevalence to the initial was performed by χ2 analysis at a significance level of P < .05.
Figure 2.
Figure 2.. Comparison of Laboratory Abnormalities Among Different SARS-CoV-2 Clades
Box and whiskers plot display first through 99th percentile laboratory results among patients infected with specific SARS-CoV-2 clades. P values for ordinary 1-way analysis of variance was performed at a significance level of P < .05. ALC indicates absolute lymphocyte count; IL-6, interleukin-6; WBC, white blood cell count. SI conversion factors: To convert ALC to cells times 109 per liter, multiply by 0.001; creatinine to micromoles per liter, multiply by 88.4; D-dimer to nanomoles per liter, multiply by 5.476; ferritin to micrograms per liter, multiply by 1.0; white blood cell count to cells times 109 per liter, multiply by 0.001.

Similar articles

Cited by

References

    1. Centers for Disease Control and Prevention . COVID data tracker. Accessed November 20, 2020. https://covid.cdc.gov/covid-data-tracker/#trends_dailytrendscases
    1. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus Disease 2019 Case Surveillance—United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(24):759-765. doi: 10.15585/mmwr.mm6924e2 - DOI - PMC - PubMed
    1. Worobey M, Pekar J, Larsen BB, et al. The emergence of SARS-CoV-2 in Europe and the US. bioRxiv. Published online May 23, 2020. doi: 10.1101/2020.05.21.109322 - DOI - PMC - PubMed
    1. Horwitz LI, Jones SA, Cerfolio RJ, et al. Trends in COVID-19 risk-adjusted mortality rates. J Hosp Med. 2021;16(2):90-92. doi: 10.12788/jhm.3552 - DOI - PubMed
    1. Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. Published online April 27, 2020. doi: 10.1093/cid/ciaa478 - DOI - PMC - PubMed

Publication types